DEACC29A-6DEF-4728-AFEB-15D7BDA850CA
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.013140604467806
- age_years
- 60
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.589
- MYC_TARGETS_V1+0.563
- DNA_REPAIR+0.534
- OXIDATIVE_PHOSPHORYLATION+0.472
- E2F_TARGETS+0.383
- CHOLESTEROL_HOMEOSTASIS+0.316
- UNFOLDED_PROTEIN_RESPONSE+0.295
- PANCREAS_BETA_CELLS+0.256
- G2M_CHECKPOINT+0.249
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.243
Top 10 suppressed
- UV_RESPONSE_DN-0.441
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.336
- KRAS_SIGNALING_DN-0.315
- INFLAMMATORY_RESPONSE-0.298
- TNFA_SIGNALING_VIA_NFKB-0.298
- IL6_JAK_STAT3_SIGNALING-0.259
- TGF_BETA_SIGNALING-0.256
- MITOTIC_SPINDLE-0.233
- ESTROGEN_RESPONSE_EARLY-0.227
- APICAL_JUNCTION-0.211
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EEE5E45B-D2E3-4CFA-AC5F-8AE1EC2CB61C | — | — | 0.912 |
| 2 | F9FA52F2-BD53-4CE8-B227-5936AE06B76A | — | — | 0.890 |
| 3 | D42E39B0-7962-4880-A182-4596DB01B202 | — | — | 0.873 |
| 4 | 4EBF33F3-DA34-4866-81E5-F2D50A18D413 | — | — | 0.871 |
| 5 | CA985B0C-E8F9-4682-ABAF-A0E482F7DF72 | — | — | 0.868 |
| 6 | FFAA0A2D-49B7-4491-9B22-C82CCF1501D0 | — | — | 0.853 |
| 7 | 13CA931D-C2D3-485E-9B18-A21B624C602E | — | — | 0.850 |
| 8 | E753A375-575A-4A0D-B231-0EC8D76BAF13 | — | — | 0.836 |
| 9 | SRR12475152 | — | — | 0.820 |
| 10 | SRR17866821 | — | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.589 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.563 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.534 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.472 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.383 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.316 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.295 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.256 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.249 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.243 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.221 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.216 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.209 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.168 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.157 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.128 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |